Birchview Capital’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Birchview Capital’s Portfolio CELGZ Stock Details CELGZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-241,877	Closed	-$98K	–	57
2018 Q2	$98K	Hold	241,877	–	–	0.07%	51
2018 Q1	$70K	Sell	241,877 -50,000	-17%	-$32.8K	0.05%	49
2017 Q4	$283K	Hold	291,877	–	–	0.17%	31
2017 Q3	$443K	Hold	291,877	–	–	0.23%	25
2017 Q2	$360K	Hold	291,877	–	–	0.19%	28
2017 Q1	$315K	Hold	291,877	–	–	0.18%	29
2016 Q4	$300K	Buy	291,877 +53,663	+23%	+$60.3K	0.18%	28
2016 Q3	$248K	Hold	238,214	–	–	0.14%	32
2016 Q2	$348K	Hold	238,214	–	–	0.25%	26
2016 Q1	$312K	Hold	238,214	–	–	0.22%	29
2015 Q4	$286K	Hold	238,214	–	–	0.16%	33
2015 Q3	$384K	Buy	238,214 +24,782	+12%	+$47.8K	0.25%	27
2015 Q2	$444K	Hold	213,432	–	–	0.23%	27
2015 Q1	$634K	Hold	213,432	–	–	0.33%	24
2014 Q4	$672K	Buy	+213,432	New	+$720K	0.39%	22

Other funds holding CELGZ

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

FCG Advisors Chatham, New Jersey $425M AUM 12.09% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

DAM

Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return

DAS

Dynamic Advisor Solutions Phoenix, Arizona $3.53B AUM 22.61% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return

BFA

Beaumont Financial Advisors Needham, Massachusetts $1.46B AUM 21.07% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Birchview Capital's CELGZ Position: Q3 2018 in Review

Birchview Capital sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q3 2018, closing a stake of 241,877 shares — an estimated $98K sold.

Birchview Capital first reported a position in CELGZ in Q4 2014 and held it in 15 quarters. The position peaked at $672K in Q4 2014. 20 funds tracked by Wall St. Rank hold CELGZ as of Q3 2018.

Birchview Capital reported no remaining Celgene Corporation Contingent Value Rights position as of Q3 2018 after selling out during the quarter.
Birchview Capital sold 241,877 Celgene Corporation Contingent Value Rights shares in Q3 2018, an estimated $98K.
Birchview Capital first reported a position in Celgene Corporation Contingent Value Rights in Q4 2014 and held it in 15 quarters.
Birchview Capital's Celgene Corporation Contingent Value Rights position peaked at $672K in Q4 2014.
20 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q3 2018.

Based on Birchview Capital's 13F filing for Q3 2018, filed 1 Nov 2018.